VANDETANIB

Background Information:

A potent and selective inhibitor (antagonist) of VEGFR (vascular
endothelial growth factor receptor), EGFR (epidermal growth factor
receptor) and RET (Rearranged during Transfection) tyrosine kinases.

Reference:

1. Deshpande HA, Gettinger SN, Sosa JA. Targeted therapy for thyroid
cancer: An updated review of investigational agents. Curr Opin Investig
Drugs. 2010 Jun;11(6):661-8.
2. Scagliotti G, Govindan R. Targeting angiogenesis with multitargeted
tyrosine kinase inhibitors in the treatment of non-small cell lung
cancer. Oncologist. 2010;15(5):436-46.
3. Rossi A, Maione P, Sacco PC, Ambrosio R, Falanga M, Gridelli C.
Vascular endothelial growth factor receptor as target for advanced
non-small cell lung cancer therapy. Curr Drug Targets. 2010
Jul;11(7):865-8784.

APIM050252: VANDETANIB

CAS No.: 443913-73-3.
Molecular Formula: C₂₂H₂₄BrFN₄O_2.
Molecular Weight: 475.4.
Purity: >99% (HPLC).
QC: ¹HNMR, HPLC.
Solubility: Soluble in DMSO.
Storage: Store at 0°C (short term), -20°C (long term), desiccated.